Patent 7094427 was granted and assigned to Impax Laboratories on August, 2006 by the United States Patent and Trademark Office.
The present invention relates to dosage forms of a combination of carbidopa and levodopa comprising both immediate release and controlled release components for the treatment of ailments associated with depleted amounts of dopamine in a patient's brain tissue.